Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 1,700 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,700 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total transaction of $279,208.00. Following the sale, the director owned 4,556 shares of the company’s stock, valued at $748,277.44. This trade represents a 27.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The stock was sold at an average price of $130.06, for a total value of $130,060.00.
• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.

Guardant Health Trading Down 3.4%

GH traded down $5.60 during midday trading on Thursday, reaching $157.58. The company’s stock had a trading volume of 1,513,030 shares, compared to its average volume of 2,317,783. The company has a fifty day simple moving average of $145.75 and a 200 day simple moving average of $114.50. The stock has a market cap of $21.15 billion, a P/E ratio of -45.15 and a beta of 1.60. Guardant Health, Inc. has a twelve month low of $48.25 and a twelve month high of $176.58.

Analyst Ratings Changes

A number of brokerages have weighed in on GH. Royal Bank Of Canada increased their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Wolfe Research initiated coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Bank of America boosted their price target on Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a research note on Monday, July 6th. TD Cowen raised their price objective on Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Stephens lifted their price objective on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $183.78.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC acquired a new position in Guardant Health during the fourth quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the 4th quarter valued at $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter worth about $35,000. Parallel Advisors LLC grew its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new stake in shares of Guardant Health during the 1st quarter worth about $38,000. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.